Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series

Peter E H Schwarz, Patrick Timpel, Lorenz Harst, Colin J Greaves, Mohammed K Ali, Jeffrey Lambert, Mary Beth Weber, Mohamad M Almedawar, Henning Morawietz, Peter E H Schwarz, Patrick Timpel, Lorenz Harst, Colin J Greaves, Mohammed K Ali, Jeffrey Lambert, Mary Beth Weber, Mohamad M Almedawar, Henning Morawietz

Abstract

The primary objective of this study was to analyze the most up-to-date evidence regarding whether and how blood sugar regulation influences cardiovascular health promotion and disease prevention by carrying out an umbrella review. Three separate, systematic literature searches identified 2,343 papers in total. Overall, 44 studies were included for data extraction and analysis. The included systematic reviews and meta-analyses published between January 1, 2016, and December 31, 2017, were of good to very good quality (median Overview Quality Assessment Questionnaire score = 17). Identified evidence suggests that cardiovascular disease (CVD) prevention services should consider regulation of blood glucose as a key target for intervention. Furthermore, the recommendations for effective intervention and service development/training described here for prevention of CVD should be adopted into evidence-based practice guidelines. Multidisciplinary teams should be formed to deliver multicomponent interventions in community-based settings. There may be substantial opportunities for integrating CVD and diabetes prevention services.

Keywords: blood glucose; diabetes mellitus; diet; exercise; health behavior; umbrella review; weight loss.

Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Figures

FIGURE 1:. PRISMA Flow Chart of study…
FIGURE 1:. PRISMA Flow Chart of study selection process
PRISMA Flow Chart shows the study selection process covering the single steps of identification via two-step-screening (title and abstract as well as full text base) for eligibility and inclusion into qualitative synthesis of this review.
FIGURE 2:. Blood Sugar Regulation: Logic Order…
FIGURE 2:. Blood Sugar Regulation: Logic Order and Interdependencies
Cardiovascular disease (CVD) risk is influenced by blood glucose regulation, and both CVD risk and blood glucose regulation are influenced by interventions targeting pathophysiological mechanisms (1a, 1b). Other risk factors also affect CVD risk. Blood glucose regulation and other risk factors are, in turn, influenced by changes in behavioral risk factors. Population-level (3a, 3b) and individual-level (2a, 2b) interventions and intervention components influence the behavioral risk factors, influencing blood glucose regulation and, ultimately, CVD risk. Boxes represent the objectives of the individual review sections; arrows show the interdependencies of the objectives for their contribution to the explanation of CVD risk.

References

    1. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017.
    1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2095–128.
    1. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Rayner M, Townsend N. European Cardiovascular Disease Statistics 2017. Brussels: European Heart Network, 2017.
    1. Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. PharmacoEconomics 2015;33:811–831.
    1. Hong KN, Fuster V, Rosenson RS, Rosendorff C, Bhatt DL. How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. J Am Coll Cardiol 2017;70:2171–2185.
    1. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147–2155.
    1. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–40.
    1. Ali MK, Bullard KM, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol 2018;6:392–403.
    1. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016;355:i5953.
    1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.
    1. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.
    1. Waugh N, Shyangdan D, Taylor-Phillips S, Suri G, Hall B. Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess 2013;17:Chapter 4.
    1. The Emerging Risk Factors Collaboration, Angelantonio ED, Gao P et al. Glycated Hemoglobin Measurement and Prediction of Cardiovascular Disease. JAMA 2014;311:1225–1233.
    1. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765–72.
    1. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–2298.
    1. Labarthe DR, Dunbar SB. Global cardiovascular health promotion and disease prevention: 2011 and beyond. Circulation 2012;125:2667–76.
    1. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008;358:2545–2559.
    1. Chou CY, Chang YT, Yang JL et al. Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis. Sci Rep 2017;7:15795.
    1. Wu JH, Foote C, Blomster J et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411–9.
    1. Schwarz PE, Greaves CJ, Lindstrom J, Yates T, Davies MJ. Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:363–373.
    1. Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. J Am Coll Cardiol 2017;70:883–893.
    1. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood) 2016;241:1323–31.
    1. Glumer C, Yuyun M, Griffin S et al. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006;49:1536–44.
    1. Williamson DF, Narayan KMV. Identification of persons with dysglycemia: Terminology and practical significance. Prim Care Diabetes 2009. 3:211–217.
    1. Echouffo-Tcheugui JB, Ali MK, Griffin SJ, Narayan KMV. Screening for Type 2 Diabetes and Dysglycemia. Epidemiol Revi 2011;33:63–87.
    1. Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ 2017;356:i6538.
    1. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008;358:2560–2572.
    1. Colagiuri R, Colagiuri S, Yach D, Pramming S. The answer to diabetes prevention: science, surgery, service delivery, or social policy? Am J Public Health 2006;96:1562–9.
    1. Nielsen SJ, Popkin BM. Patterns and trends in food portion sizes, 1977–1998. JAMA 2003;289:450–3.
    1. Brownell KD, Farley T, Willett WC et al. The public health and economic benefits of taxing sugar-sweetened beverages. N Engl J Med 2009;361:1599–605.
    1. Novak NL, Brownell KD. Taxation as prevention and as a treatment for obesity: the case of sugar-sweetened beverages. Curr Pharm Des 2011;17:1218–22.
    1. Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med 2007;357:370–9.
    1. Elbel B, Kersh R, Brescoll VL, Dixon LB. Calorie labeling and food choices: a first look at the effects on low-income people in New York City. Health Aff (Millwood) 2009;28:w1110–21.
    1. Rose G Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed) 1981;282:1847–1851.
    1. Martin GP, Kocman D, Stephens T, Peden CJ, Pearse RM. Pathways to professionalism? Quality improvement, care pathways, and the interplay of standardisation and clinical autonomy. Sociol Health Illn 2017;39:1314–1329.
    1. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc 2015;13:132–140.
    1. Andersen RM. Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? J Health Soc Behav 1995;36:1–10.
    1. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991;44:1271–1278.
    1. Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
    1. Greaves CJ, Sheppard KE, Abraham C et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health 2011;11:1–12.
    1. Dong X, Cai R, Sun J et al. Diabetes as a risk factor for acute coronary syndrome in women compared with men: a meta-analysis, including 10 856 279 individuals and 106 703 acute coronary syndrome events. Diabetes Metab Res Rev 2017;33.
    1. Bundhun PK, Bhurtu A, Yuan J. Impact of type 2 diabetes mellitus on the long-term mortality in patients who were treated by coronary artery bypass surgery: A systematic review and meta-analysis. Medicine 2017;96:e7022.
    1. Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014–9.
    1. Straumann E, Kurz DJ, Muntwyler J et al. Admission glucose concentrations independently predict early and late mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention. Am Heart J 2005;150:1000–6.
    1. Chen PC, Chua SK, Hung HF et al. Admission hyperglycemia predicts poorer short‐ and long‐term outcomes after primary percutaneous coronary intervention for ST‐elevation myocardial infarction. J Diabetes Invest 2014;5:80–86.
    1. Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes in patients with acute coronary syndromes: The global registry of acute coronary events. Arch Intern Med 2004;164:1457–1463.
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.
    1. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59.
    1. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–39.
    1. Li J, Tong Y, Zhang Y et al. Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials. Clin Ther 2016;38:372–386.e6.
    1. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017;60:1620–1629.
    1. Fang H-J, Zhou Y-H, Tian Y-J, Du H-Y, Sun Y-X, Zhong L-Y. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials. Int J Cardiol 2016;218:50–58.
    1. Zoungas S, Arima H, Gerstein HC et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431–437.
    1. Savarese G, D’Amore C, Federici M et al. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. Int J Cardiol 2016;220:595–601.
    1. Wang T, Wang F, Zhou J, Tang H, Giovenale S. Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes Metab Res Rev 2016;32:843–857.
    1. Packer M Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials. Circ Res 2018;122:928–932.
    1. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017;19:216–227.
    1. Zhang Z, Chen X, Lu P et al. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol 2017;16:31.
    1. Gargiulo P, Savarese G, D’Amore C et al. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. Nutr Metab Cardiovasc Dis 2017. 27:1081–1088.
    1. Rizzo M, Nikolic D, Patti AM et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta 2018.
    1. Baker WL, Buckley LF, Kelly MS et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2017;6.
    1. Johnston R, Uthman O, Cummins E et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2017;21:1–218.
    1. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. J Am Heart Assoc 2017;6.
    1. Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol 2017;54:19–36.
    1. Sha S, Polidori D, Heise T et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:1087–95.
    1. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587–97.
    1. Bonner C, Kerr-Conte J, Gmyr V et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512–7.
    1. Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499–508.
    1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811–21.
    1. Cherney DZ, Perkins BA, Soleymanlou N et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28.
    1. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002;106:2085–90.
    1. Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Diabet Med 2016;33:280–9.
    1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017;35:922–944.
    1. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016;352:i717.
    1. Beck J, Greenwood DA, Blanton L et al. 2017 National Standards for Diabetes Self-Management Education and Support. Diabetes Care 2017.
    1. National Institute for Health and Clinical Excellence - NICE. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. NICE public health guidance; 38 Last updated: September 2017. ed, 2012.
    1. Cai X, Qiu SH, Yin H et al. Pedometer intervention and weight loss in overweight and obese adults with Type 2 diabetes: a meta-analysis. Diabet Med 2016;33:1035–44.
    1. Ekong G, Kavookjian J. Motivational interviewing and outcomes in adults with type 2 diabetes: A systematic review. Patient Educ Couns 2015;99:944–52.
    1. Joiner KL, Nam S, Whittemore R. Lifestyle interventions based on the diabetes prevention program delivered via eHealth: A systematic review and meta-analysis. Prev Med 2017;100:194–207.
    1. Modesti PA, Galanti G, Cala P, Calabrese M. Lifestyle interventions in preventing new type 2 diabetes in Asian populations. Intern Emerg Med 2015;11:375–84.
    1. Porter J, Huggins CE, Truby H, Collins J. The Effect of Using Mobile Technology-Based Methods That Record Food or Nutrient Intake on Diabetes Control and Nutrition Outcomes: A Systematic Review. Nutrients 2016;8.
    1. Thepwongsa I, Muthukumar R, Kessomboon P. Motivational interviewing by general practitioners for Type 2 diabetes patients: a systematic review. Family practice 2017;34:376–383.
    1. Zhu H, Zhu Y, Leung SW. Is self-monitoring of blood glucose effective in improving glycaemic control in type 2 diabetes without insulin treatment: a meta-analysis of randomised controlled trials. BMJ open 2016;6:e010524.
    1. Arambepola C, Ricci-Cabello I, Manikavasagam P, Roberts N, French DP, Farmer A. The Impact of Automated Brief Messages Promoting Lifestyle Changes Delivered Via Mobile Devices to People with Type 2 Diabetes: A Systematic Literature Review and Meta-Analysis of Controlled Trials. J Med Internet Res 2016;18:e86.
    1. Baskerville R, Ricci-Cabello I, Roberts N, Farmer A. Impact of accelerometer and pedometer use on physical activity and glycaemic control in people with Type 2 diabetes: a systematic review and meta-analysis. Diabetic medicine : a journal of the British Diabetic Association;34:612–620.
    1. Beishuizen CR, Stephan BC, van Gool WA et al. Web-Based Interventions Targeting Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review and Meta-Analysis. J Med Internet Res 2016;18:e55.
    1. Cradock KA, G OL, Finucane FM et al. Diet Behavior Change Techniques in Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care 2017;40:1800–1810.
    1. Cui M, Wu X, Mao J, Wang X, Nie M. T2DM Self-Management via Smartphone Applications: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166718.
    1. Daly B, Tian CJL, Scragg RKR. Effect of nurse-led randomised control trials on cardiovascular risk factors and HbA1c in diabetes patients: A meta-analysis. Diabetes Res Clin Pract 2017;131:187–199.
    1. Fu S, Li L, Deng S, Zan L, Liu Z. Effectiveness of advanced carbohydrate counting in type 1 diabetes mellitus: a systematic review and meta-analysis. Sci Rep 2016;6:37067.
    1. Joiner KL, Nam S, Whittemore R. Lifestyle interventions based on the diabetes prevention program delivered via eHealth: A systematic review and meta-analysis. Prev Med 2017;100:194–207.
    1. Moller G, Andersen HK, Snorgaard O. A systematic review and meta-analysis of nutrition therapy compared with dietary advice in patients with type 2 diabetes. Am J Clin Nutr 2017;106:1394–1400.
    1. Mudaliar U, Zabetian A, Goodman M et al. Cardiometabolic Risk Factor Changes Observed in Diabetes Prevention Programs in US Settings: A Systematic Review and Meta-analysis. PLoS Med 2016;13:e1002095.
    1. Odgers-Jewell K, Ball LE, Kelly JT, Isenring EA, Reidlinger DP, Thomas R. Effectiveness of group-based self-management education for individuals with Type 2 diabetes: a systematic review with meta-analyses and meta-regression. Diabet Med 2017;34:1027–1039.
    1. Pousinho S, Morgado M, Falcao A, Alves G. Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. J Manag Care Spec Pharm 2016;22:493–515.
    1. Taylor J, Stubbs B, Hewitt C et al. The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis. PLoS One 2017;12:e0168549.
    1. Sun Y, You W, Almeida F, Estabrooks P, Davy B. The Effectiveness and Cost of Lifestyle Interventions Including Nutrition Education for Diabetes Prevention: A Systematic Review and Meta-Analysis. J Acad Nutr Diet 2017;117:404–421.e36.
    1. Wang Y, Xue H, Huang Y, Huang L, Zhang D. A Systematic Review of Application and Effectiveness of mHealth Interventions for Obesity and Diabetes Treatment and Self-Management. Adv Nutr 2017;8:449–462.
    1. Yasmin F, Banu B, Zakir SM, Sauerborn R, Ali L, Souares A. Positive influence of short message service and voice call interventions on adherence and health outcomes in case of chronic disease care: a systematic review. BMC Med Inform Decis Mak 2016;16:46.
    1. Zhang X, Imperatore G, Thomas W et al. Effect of lifestyle interventions on glucose regulation among adults without impaired glucose tolerance or diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2016;123:149–164.
    1. Deylami R, Townson J, Mann M, Gregory JW. Systematic review of publicity interventions to increase awareness amongst healthcare professionals and the public to promote earlier diagnosis of type 1 diabetes in children and young people. Pediatr Diabetes 2017.
    1. Reed JL, Prince SA, Elliott CG et al. Impact of Workplace Physical Activity Interventions on Physical Activity and Cardiometabolic Health Among Working-Age Women: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes 2017;10.
    1. Shrestha A, Karmacharya BM, Khudyakov P, Weber MB, Spiegelman D. Dietary Interventions to Prevent and Manage Diabetes in Worksite Settings: a Meta-Analysis. J Occup Health 2017.
    1. Ebireri J, Aderemi AV, Omoregbe N, Adeloye D. Interventions addressing risk factors of ischaemic heart disease in sub-Saharan Africa: a systematic review. BMJ Open 2016;6:e011881.
    1. Grace JM, Wilder CJ, Strydom GI. The effect of a physical and a combined health promotion intervention programme on some selected health indicators on South African colliery executives. South Afr J Res Sports, Phys Educ Recreation 2009;31:9–18.
    1. Gourzoulidis G, Kourlaba G, Stafylas P, Giamouzis G, Parissis J, Maniadakis N. Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy 2017;121:363–377.
    1. Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control. Managed care 2009;18:47–53.
    1. Soumerai SB, Starr D, Majumdar SR. How Do You Know Which Health Care Effectiveness Research You Can Trust? A Guide to Study Design for the Perplexed. Prev Chronic Dis 2015;12:E101.
    1. Soumerai SB, Ceccarelli R, Koppel R. False Dichotomies and Health Policy Research Designs: Randomized Trials Are Not Always the Answer. J Gen Intern Med 2017;32:204–209.
    1. Basu S, Meghani A, Siddiqi A. Evaluating the Health Impact of Large-Scale Public Policy Changes: Classical and Novel Approaches. Ann Rev Public Health 2017;38:351–370.
    1. Humphreys DK, Panter J, Sahlqvist S, Goodman A, Ogilvie D. Changing the environment to improve population health: a framework for considering exposure in natural experimental studies. J Epidemiol Community Health 2016.
    1. Craig P, Katikireddi SV, Leyland A, Popham F. Natural Experiments: An Overview of Methods, Approaches, and Contributions to Public Health Intervention Research. Annu Rev Public Health 2017;38:39–56.
    1. Hill JO, Galloway JM, Goley A et al. Scientific Statement: Socioecological Determinants of Prediabetes and Type 2 Diabetes. Diabetes Care 2013;36:2430–2439.
    1. Ackermann RT, Kenrik Duru O, Albu JB et al. Evaluating diabetes health policies using natural experiments: the natural experiments for translation in diabetes study. Am J Prev Med 2015;48:747–54.
    1. Freudenberg N, Franzosa E, Sohler N, Li R, Devlin H, Albu J. The State of Evaluation Research on Food Policies to Reduce Obesity and Diabetes Among Adults in the United States, 2000–2011. Prev Chronic Dis 2015;12:E182.
    1. Goodwin N Understanding Integrated Care. Int J Integr Care 2016;16:6.
    1. Baptista DR, Wiens A, Pontarolo R, Regis L, Reis WC, Correr CJ. The chronic care model for type 2 diabetes: a systematic review. Diabetol Metab Syndr 2016;8:7.
    1. Bongaerts BWC, Müssig K, Wens J et al. Effectiveness of chronic care models for the management of type 2 diabetes mellitus in Europe: a systematic review and meta-analysis. BMJ Open 2017;7:1–16.
    1. Busetto L, Luijkx KG, Elissen AMJ, Vrijhoef HJM. Context, mechanisms and outcomes of integrated care for diabetes mellitus type 2: a systematic review. BMC Health Serv Res 2016;16:18.
    1. Babar ZU, Kousar R, Murtaza G, Azhar S, Khan SA, Curley L. Randomized controlled trials covering pharmaceutical care and medicines management: A systematic review of literature. Res Social Adm Pharm 2017:521–539.
    1. Aguiar PM, Brito Gde C, Lima Tde M, Santos AP, Lyra DP Jr., Storpirtis S Investigating Sources of Heterogeneity in Randomized Controlled Trials of the Effects of Pharmacist Interventions on Glycemic Control in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0150999.
    1. Asayut N, Sookaneknun P, Chaiyasong S, Saramunee K. Outcomes, costs and stakeholders’ perspectives associated with the incorporation of community pharmacy services into the National Health Insurance System in Thailand: a systematic review. Int J Pharm Pract 2018:16–27.
    1. Seidu S, Walker NS, Bodicoat DH, Davies MJ, Khunti K. A systematic review of interventions targeting primary care or community based professionals on cardio-metabolic risk factor control in people with diabetes. Diabetes Res Clin Pract 2016;113:1–13.
    1. Deters MA, Laven A, Castejon A et al. Effective Interventions for Diabetes Patients by Community Pharmacists: A Meta-analysis of Pharmaceutical Care Components. Ann Pharmacother 2017:1060028017733272.
    1. Greer N, Bolduc J, Geurkink E et al. Pharmacist-led Chronic Disease Management: A Systematic Review of Effectiveness and Harms Compared With Usual Care. Ann Intern Med 2016.
    1. Brown TJ, O’Malley C, Blackshaw J et al. Exploring the evidence base for Tier 3 weight management interventions for adults: a systematic review. Clin Obes 2017;7:260–272.
    1. Jeet G, Thakur JS, Prinja S, Singh M. Community health workers for non-communicable diseases prevention and control in developing countries: Evidence and implications. PLoS One 2017;12:e0180640.
    1. Massimi A, De Vito C, Brufola I et al. Are community-based nurse-led self-management support interventions effective in chronic patients? Results of a systematic review and meta-analysis. PLoS One 2017;12:e0173617.
    1. Tabesh M, Magliano DJ, Koye DN, Shaw JE. The effect of nurse prescribers on glycaemic control in type 2 diabetes: A systematic review and meta-analysis. Int J Nurs Stud 2017.
    1. Li G, Zhang P, Wang J et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–9.
    1. The Look Ahead Research Group. Long Term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals with Type 2 Diabetes: Four Year Results of the Look AHEAD Trial. Arch Intn Med 2010;170:1566–1575.
    1. van Beurden SB, Greaves CJ, Smith J, Abraham C. Techniques for Modifying Impulsive Processes Associated with Unhealthy Eating: A Systematic Review. Health Psychol 2016;35:793–806.
    1. Kim DA, Hwong AR, Stafford D et al. Social network targeting to maximise population behaviour change: a cluster randomised controlled trial. Lancet 2015;386:145–153.
    1. Strack F, Deutsch R. Reflective and Impulsive Determinants of Social Behavior. Pers Soc Psychol Rev 2004;8:220–247.
    1. Alicia A-M, Josep MS-S, Gemma M-M, Medina FX, Ramon C-C, Francesc S-R. Use of mobile phones as a tool for weight loss: a systematic review. J Telemed Telecare 2014;20:339–349.
    1. Hafez D, Fedewa A, Moran M, O’Brien M, Ackermann R, Kullgren JT. Workplace Interventions to Prevent Type 2 Diabetes Mellitus: a Narrative Review. Curr Diab Rep 2017;17:9.
    1. Pomeranz JL, Wilde P, Huang Y, Micha R, Mozaffarian D. Legal and Administrative Feasibility of a Federal Junk Food and Sugar-Sweetened Beverage Tax to Improve Diet. Am J Public Health 2018;108:203–209.
    1. Malambo P, Kengne AP, De Villiers A, Lambert EV, Puoane T. Built Environment, Selected Risk Factors and Major Cardiovascular Disease Outcomes: A Systematic Review. PLoS One 2016;11:e0166846.
    1. Wright A, Smith KE, Hellowell M. Policy lessons from health taxes: a systematic review of empirical studies. BMC Public Health 2017;17:583.
    1. Schwarz PE, Riemenschneider H. Slowing Down the Progression of Type 2 Diabetes: We Need Fair, Innovative, and Disruptive Action on Environmental and Policy Levels! Diabetes Care 2016;39 Suppl 2:S121–6.
    1. Minneboo M, Lachman S, Snaterse M et al. Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease: The RESPONSE-2 Trial. J Am Coll Cardiol 2017;70:318–327.
    1. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–847.
    1. Smith SM, Wallace E, O’Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev 2016;3:Cd006560.
    1. Cronin J, Murphy A, Savage E. Can chronic disease be managed through integrated care cost-effectively? Evidence from a systematic review. Ir J Med Sci 2017;186:827–834.
    1. OECD. Cardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care, 2015.
    1. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal 2016;37:2315–2381.
    1. Michie S, Richardson M, Johnston M et al. The Behavior Change Technique Taxonomy (v1) of 93 Hierarchically Clustered Techniques: Building an International Consensus for the Reporting of Behavior Change Interventions. Ann Behav Med 2013;46:81–95.
    1. Dunkley AJ, Bodicoat DH, Greaves CJ et al. Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations: A Systematic Review and Meta-analysis. Diabetes Care 2014;37:922–933.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅